期刊文献+

第21号外显子L858R缺失突变肺腺癌患者临床特征分析

Analysis of clinical characteristics of lung adenocarcinoma patients with exon 21 L858R deletion mutation
原文传递
导出
摘要 目的探讨第21号外显子L858R缺失突变肺腺癌患者的临床特征。方法回顾性分析2015年1月至2018年12月新疆维吾尔自治区人民医院明确诊断为肺腺癌且基因检测阳性的112例患者资料,分为第21号外显子L858R缺失突变组(52例)和非第21号外显子L858R缺失突变组(60例),比较两组患者的临床特点、影像学特征、肿瘤标志物表达情况及吸烟史。结果第21号外显子L858R缺失突变组与非第21号外显子L858R缺失突变组的性别、年龄、民族比较,差异均无统计学意义(P值分别为0.488、0.238、0.191);影像学特征(包括原发肿瘤部位、分叶征、毛刺征、胸膜凹陷征、空泡征)比较,差异均无统计学意义(均P>0.05);肿瘤标志物(包括癌胚抗原、鳞状细胞癌抗原、神经元特异性烯醇化酶、细胞角蛋白19片段、胃泌素释放肽前体)表达情况比较,差异均无统计学意义(均P>0.05)。第21号外显子L858R缺失突变组有吸烟史20例(38.5%,20/52),非第21号外显子L858R缺失突变组有吸烟史4例(6.7%,4/60),两组差异有统计学意义(χ^2=4.182,P=0.041)。结论第21号外显子L858R缺失突变肺腺癌患者的临床特点、影像学特征、肿瘤标志物表达情况与非第21号外显子L858R缺失突变者无明显差异,吸烟可能是发生第21号外显子L858R缺失突变的影响因素。 Objective To explore the clinical characteristics of lung adenocarcinoma patients with exon 21 L858R deletion mutation.Methods The data of 112 patients who were diagnosed with lung adenocarcinoma and positive genetic mutations in the People's Hospital of Xinjiang Uygur Autonomous Region from January 2015 to December 2018 was retrospectively analyzed,and the patients were divided into the exon 21 L858R deletion mutation group(52 cases)and the non-exon 21 L858R deletion mutation group(60 cases).The clinical characteristics,imaging characteristics,expressions of tumor markers and smoking history of patients were compared between the two groups.Results There was no statistical difference in the gender,age and ethnicity between the exon 21 L858R deletion mutation group and the non-exon 21 L858R deletion mutation group(P values were 0.488,0.238 and 0.191).There was no statistical difference in the imaging features(including primary tumor site,lobulation,burr,pleural depression and small vacuoles)between the two groups(all P>0.05).There was no statistical difference in the expressions of tumor markers(including carcinoembryonic antigen,squamous cell carcinoma antigen,neuron-specific enolase,cytokeratin 19 fragment,and gastrin-releasing peptide precursor)between the two groups(all P>0.05).There were 20 patients(38.5%,20/52)with smoking history in the exon 21 L858R deletion mutation group,and 4 patients(6.7%,4/60)with smoking history in the non-exon 21 L858R deletion mutation group,the difference between the two groups was statistically significant(χ^2=4.182,P=0.041).Conclusions There is no significant difference in clinical characteristics,imaging features and expressions of tumor markers between the patients with exon 21 L858R deletion mutation and the patients without exon 21 L858R deletion mutation.Smoking may be the influencing factor of exon 21 L858R deletion mutation.
作者 冷秋平 矫捷 杨晓红 Leng Qiuping;Jiao Jie;Yang Xiaohong(Department of Respiratory and Critical Care Medicine,the People's Hospital of Xinjiang Uygur Autonomous Region,Urumqi 830002,China;Department of Respiratory and Critical Care Medicine,Fuding City Hospital of Fujian Province,Fuding 355200,China)
出处 《肿瘤研究与临床》 CAS 2020年第4期271-274,共4页 Cancer Research and Clinic
关键词 肺肿瘤 腺癌 突变 Lung neoplasms Adenocarcinoma Mutation
  • 相关文献

参考文献6

二级参考文献78

  • 1王金万,孙燕.重组人血管内皮抑素Ⅲ期临床研究[J].中国医疗前沿,2006(3):87-90. 被引量:5
  • 2Soda M,Choi YL,Enomoto M,et al.Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.Nature,2007,448(7153):561-566. 被引量:1
  • 3Wong DW,Leung EL,So KK,et al.The EML4 ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS.Cancer,2009,115(8):1723-1733. 被引量:1
  • 4Shaw AT,Yeap BY,Mino-Kenudson M,et al.Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.J Clin Oncol,2009,27(26):4247-4253. 被引量:1
  • 5Shaw AT.Phase 3 randomized study of crizotinib versus pemetrexed or docetaxel chemotherapy in advanced,ALK-positive NSCLC (PROFILE 1007).35th ESMO,2012,abstract LBA1. 被引量:1
  • 6全国肿瘤防治研究办公室/全国肿瘤登记中心/卫生部疾病预防控制局.2009全国肿瘤登记年报.北京:军事医学科学出版社.2010. 被引量:1
  • 7Rikova K,Guo A,Zeng Q,et al.Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer.Cell,2007,131 (6):1190-1203. 被引量:1
  • 8Mitsudomi T,Suda K,Tomizawa K,et al.Clinico-pathologic features of lung cancer with EML4-ALK translocation.J Clin Oncol,2010 (suppl):abstr 10598. 被引量:1
  • 9Zhang X,Zhang S,Yang X,et al.Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression.Mol Cancer,2010,9:188. 被引量:1
  • 10Wu SG,Kuo YW,Chang YL,et al.EML4-ALK translocation predicts better outcome in lung adenocarcinoma patients with wildtype EGFR.J Thorac Oucol,2012,7(1):98-104. 被引量:1

共引文献256

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部